CDK1 and neoplasm: Importantly, previous studies have reported that CDK1 inhibitor RO-3306 exhibits tumor-selective cytotoxicity, demonstrating up to a fourfold greater cell-killing efficacy in bladder carcinoma and laryngeal squamous cell carcinoma models compared to normal epithelial cells [49].